Our in vitro studies confirmed that IL‐1α/β treatment significantly reduces PGC‐1α and FXR‐α mRNA levels in the human hepatoma cell line HepG2, in human and mouse primary hepatocytes, as previously reported.62 Here, PPARGC1A is linked to hepatocellular carcinoma.